Testing a Tumor Vaccine Plus Vorasidenib for IDH1 Mutant Lower Grade Glioma That Came Back
Official title: ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests a tumor vaccine given with a drug called vorasidenib.
Read our full plain-language summary
What the trial team says
The purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in adult patients diagnosed with recurrent IDH1 mutant lower grade gliomas.
Key facts
- Registry number
- NCT05609994
- Stage of testing
- Phase 1
- Conditions studied
- Low Grade Glioma of Brain
Where it is running
This trial lists 1 site.
-
North Carolina
- Duke University Medical Center (Durham)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.